Bridging the Gap Between Dermatology, Primary Care, and Pediatric Care for Patients With Moderate-to-Severe Atopic Dermatitis
John J. Russell, MD
Chair Department of Family Medicine
Director, Medical Education / Designated Institutional Official
Associate Program Director
Family Medicine Residency Program
Jefferson-Abington Hospital
Abington, Pennsylvania
Micromodule 1: Moderate-to-Severe AD in Pediatric vs Adult Patients
PROGRAM OVERVIEW
This innovative online enduring activity is designed to enhance clinicians’ understanding and management of atopic dermatitis (AD). It equips healthcare professionals with the knowledge to recognize the clinical characteristics of AD, highlighting key differences between adults and pediatric presentations. The program also explores the therapeutic benefits of biologics for patients with moderate-to-severe AD. Additionally, it promotes a multidisciplinary team (MDT) approach to improve collaboration across specialties, emphasizing timely dermatology referrals for optimal patient care.
TARGET AUDIENCE
This activity is intended for dermatologists, pediatricians, primary care physicians (PCPs), and other healthcare professionals involved in the management of pediatric and adult patients with moderate-to-severe AD.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the clinical presentation features of AD and differentiators for in adult compared with pediatric cases
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a Med Learning Group–sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| John J. Russell, MD | Consulting Fees: GlaxoSmithKline, Pfizer Inc., Sanofi, and Moderna, Inc. Speaker’s Bureau: Sanofi |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and a nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this continuing education (CE) activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Deborah Anderson, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- A nurse reviewer has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both US Food and Drug Administration (FDA)-approved and non-FDA-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use their clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASED DATE: September 30, 2025
EXPIRATION DATE: September 30, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited
Lisa Arkin, MD
Associate Professor of Dermatology and Pediatrics
Director of Pediatric Dermatology
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin
Micromodule 2: Use of Biologics for Moderate-to-Severe Atopic Dermatitis
PROGRAM OVERVIEW
This innovative online enduring activity is designed to enhance clinicians’ understanding and management of atopic dermatitis (AD). It equips healthcare professionals with the knowledge to recognize the clinical characteristics of AD, highlighting key differences between adults and pediatric presentations. The program also explores the therapeutic benefits of biologics for patients with moderate-to-severe AD. Additionally, it promotes a multidisciplinary team (MDT) approach to improve collaboration across specialties, emphasizing timely dermatology referrals for optimal patient care.
TARGET AUDIENCE
This activity is intended for dermatologists, pediatricians, primary care physicians (PCPs), and other healthcare professionals involved in the management of pediatric and adult patients with moderate-to-severe AD.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Explain the therapeutic potential of biologics for patients with moderate-to-severe AD
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a Med Learning Group–sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Lisa Arkin, MD | Consulting Fees: Merck & Co., Inc., Eli Lilly and Company, Regeneron Pharmaceuticals, and Sanofi Contracted Research: Eli Lilly and Company, Amgen, and Incyte (funds to the institution) |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and a nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this continuing education (CE) activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Deborah Anderson, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- A nurse reviewer has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture the faculty may mention the use of medications for both US Food and Drug Administration (FDA)-approved and non-FDA-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use their clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASED DATE: September 30, 2025
EXPIRATION DATE: September 30, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited
Peter A. Lio, MD
Clinical Assistant Professor, Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Medical Dermatology Associates of Chicago
Chicago, Illinois
Micromodule 3: Multidisciplinary Care Framework to Provide Patient Care
PROGRAM OVERVIEW
This innovative online enduring activity is designed to enhance clinicians’ understanding and management of atopic dermatitis (AD). It equips healthcare professionals with the knowledge to recognize the clinical characteristics of AD, highlighting key differences between adults and pediatric presentations. The program also explores the therapeutic benefits of biologics for patients with moderate-to-severe AD. Additionally, it promotes a multidisciplinary team (MDT) approach to improve collaboration across specialties, emphasizing timely dermatology referrals for optimal patient care.
TARGET AUDIENCE
This activity is intended for dermatologists, pediatricians, primary care physicians (PCPs), and other healthcare professionals involved in the management of pediatric and adult patients with moderate-to-severe AD.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Employ an MDT approach to streamline collaboration among specialties starting with prompt dermatology referral for patients with moderate-to-severe AD
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a Med Learning Group–sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Peter Lio, MD | Speaker’s Bureaus: AbbVie, Arcutis Biotherapeutics, Eli Lilly and Company, Galderma Laboratories, Hyphens Pharma, Incyte Corporation, La Roche-Posay (L’Oréal Group), Pfizer Inc., Pierre Fabre, Regeneron Pharmaceuticals, Sanofi, and Verrica Pharmaceuticals Consulting / Advisory Boards: Alphyn Biologics, AbbVie, Almirall, Amyris, Apogee Therapeutics, Arcutis Biotherapeutics, Astria Therapeutics, Boston Skin Science, Bristol Myers Squibb, Burt’s Bees (The Clorox Company), Castle Biosciences, Codex Labs, Concerto Biosciences, Dermavant Sciences, Eli Lilly and Company, Galderma Laboratorie, Kenvue, LEO Pharma, Lipidor, L’Oréal Group, Merck & Co., Inc., Micreos, MyOR Diagnostics, Pelthos Therapeutics, Phyla Biotech, Regeneron Pharmaceuticals, Sanofi, Sibel Health, Skinfix, Soteri Skin, Stratum Biosciences, Sun Pharmaceutical Industries Ltd., Theraplex, UCB, Unilever, Verdant Scientific, Verrica Pharmaceuticals, and Yobee Care. Stock Options: Alphyn Biologics, Codex Labs, Concerto Biosciences, Soteri Skin, Stratum Biosciences, Thimble Health, Verdant Scientific, and Yobee Care Other Roles: Holds a patent pending for a Theraplex product, with royalties paid. Serves as Board Member and Scientific Advisory Committee Member Emeritus for the National Eczema Association |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and a nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this continuing education (CE) activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Deborah Anderson, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- A nurse reviewer has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
- Lauren Bartunek, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Heather Gee, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture the faculty may mention the use of medications for both US Food and Drug Administration (FDA)-approved and non-FDA-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use their clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com
RELEASED DATE: September 30, 2025
EXPIRATION DATE: September 30, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited
